UK medicines regulator says information on boxes of montelukast will alert users to risk of mood and behaviour changes
More than 500 adverse neuropsychiatric reactions have been reported in children under the age of nine involving an asthma drug which is to get new warnings over its risks.
The Medicines and Healthcare products Regulatory Agency (MHRA) announced last week that more prominent warnings would be added to the information provided on boxes of the asthma drug montelukast, sold under the brand name Singulair.
About Author
More Stories
Male mosquitoes to be genetically engineered to poison females with semen in Australian research
Memo to Trump: US telecoms is vulnerable to hackers. Please hang up and try again | John Naughton
Bizarre Australian mole even more unusual than first thought, new research reveals